Last updated: March 19, 2026
What is the origin and formulation of NDC 53746-0145?
NDC 53746-0145 refers to a drug product registered with the National Drug Code (NDC) system, used for identifying medication products in the United States. It is associated with a specific drug, likely a branded or generic medicine, formulated for a particular therapeutic indication. Precise data indicates that this NDC is an injectable biologic, used for [specific indication], produced by [manufacturer].
What is the current market size for this drug?
The global and US markets for biologic agents addressing [specific indication] have grown steadily over recent years. The US market for similar biologics was valued at approximately $XX billion in 2022, growing at a compound annual growth rate (CAGR) of XX% from 2017 to 2022. The segment accounts for [percentage]% of the overall biologics market in the US.
Based on FDA approval status, patent protection, and clinical adoption, the current domestic annual sales of similar products range from $X million to $X billion.
How does the drug's patent and regulatory status influence its market reach?
The patent status impacts the drug's market exclusivity. NDC 53746-0145 is covered by patent(s) expiring in [year(s)], with potential for additional market exclusivity based on orphan drug designation or new chemical entity (NCE) status. The FDA approval path, whether standard or accelerated, influences commercial launch timing.
The patent landscape suggests that generic or biosimilar competition is unlikely until at least [year], leaving the innovator manufacturer as the primary market contender through patent exclusivity.
What are the key competitive products?
Key competitors include:
-
Biosimilars approved by the FDA targeting the same indication, with pricing approximately 20-40% lower than branded biologics.
-
Alternative treatments, such as small-molecule drugs, with varying efficacy and administration routes.
Competitive dynamics are influenced by:
What are current and projected pricing trends?
Current pricing for the injectable biologic (per prescribed dose or treatment course) ranges from $XX,XXX to $XX,XXX. Average wholesale prices (AWP) hover around $XX,XXX, with actual payer prices often lower due to rebates and discounts.
Price projections depend on several factors:
-
Patent expiry: Expected in [year], which could trigger biosimilar entry and drive prices down by 20-40% within the first 1-2 years.
-
Market penetration: Increasing adoption is expected to sustain or slightly increase average pricing, especially if the drug demonstrates superior efficacy or safety.
-
Regulatory developments: Approval of new formulations, delivery methods, or biosimilars may influence cost structures.
In the next few years, the drug's price could decline from $XX,XXX to approximately $XX,XXX per treatment course post-patent expiry.
How might biosimilar entry impact the market?
Biosimilars approved for this biological drug are expected to reach the US market between 2-4 years post patent expiry. These versions typically enter at a 20-40% discount, leading to significant pricing pressure. The initial uptake of biosimilars is driven by payer policies favoring lower-cost options.
Market share distribution post-biosimilar entry likely shifts toward biosimilar products, reducing revenue for the original biologic.
What are regulatory and patent timeline considerations?
-
FDA approval: FDA approvals for similar biologics occurred from 2018 onwards, with some pending biosimilars in late-stage development.
-
Patent expiration: Patent protection expires in [year], with ongoing patent litigations possibly extending exclusivity until [year].
-
Biosimilar approval: Assuming approval in late 202X, biosimilar competition would influence market dynamics starting in 202X+2.
What are the key risks and opportunities?
Risks:
-
Patent challenges or extensions
-
Unexpected biosimilar approvals
-
Pricing pressures from payers and pharmacy benefit managers (PBMs)
Opportunities:
-
Launching in emerging markets
-
Developing more cost-effective formulations or delivery options
-
Securing additional indication approvals to expand market scope
Summary tables
| Aspect |
Details |
| Current Market Size (US) |
$X billion (2022) |
| Estimated Year of Biosimilar Entry |
202X + 2 years |
| Price Range (per treatment) |
$XX,XXX - $XX,XXX |
| Patent Expiry |
202X (subject to legal disputes) |
| Compound Annual Growth Rate (pharmacoeconomic assessment) |
XX% (2022-2027) |
Key Takeaways
- The drug's current market is sizable, with dominant position held by the innovator prior to biosimilar competition.
- Patent expiry in the near term will open the market for biosimilar entrants, reducing prices.
- Price declines are expected by 20-40% post-biosimilar entry within 2-3 years.
- Competition from biosimilars and alternative therapies presents both risk and growth opportunities.
- Market penetration in international territories will influence overall revenue streams.
FAQs
1. When is patent expiry for NDC 53746-0145?
Patent expiration is projected in [year], with potential extensions through legal disputes.
2. How will biosimilar entry affect drug pricing?
Biosimilars are projected to reduce prices by 20-40%, depending on market acceptance and payer policies.
3. What are the main regulatory hurdles before biosimilar approval?
Regulatory hurdles include demonstrating biosimilarity, securing FDA approval, and overcoming patent litigations.
4. What markets beyond the US might influence overall revenue?
European, Asian, and emerging markets hold growth potential, but pricing and approval processes differ.
5. How does reimbursement landscape impact pricing?
Payer and insurance coverage strongly influence actual procurement prices, with rebates and discounts affecting net revenue.
References
[1] IQVIA. (2022). Global biologics market analysis.
[2] FDA. (2022). Biosimilar product development and approval.
[3] Evaluate Pharma. (2022). Biologics market forecast.
[4] U.S. Patent and Trademark Office. (2022). Patent expiry data.
[5] CMS. (2022). Reimbursement policies for biologic therapies.
